Ozempic (Semaglutide)
Launch:
Ozempic was launched by Novo Nordisk in 2017.
Manufacturer:
Novo Nordisk
Global Sales in 2023:
Ozempic’s global sales in 2023 were approximately $15 billion, driven by its effectiveness in both diabetes management and weight loss.
Why It’s the Best:
Ozempic is a GLP-1 receptor agonist used in the treatment of type 2 diabetes. It helps control blood sugar levels by enhancing insulin secretion and reducing appetite, leading to significant weight loss. Its dual benefits of glycemic control and weight loss have made it a preferred treatment option for many patients. Recently, its use as a weight loss medication has further boosted its popularity.